Canada has issued its defense in a $500 million lawsuit brought by Eli Lilly & Co., saying the company is merely a “disappointed litigant” bringing a claim “wholly without merit.”
The Indianapolis-based pharmaceutical company has alleged that Canadian court rulings that invalidated two key patents violated international rules established in trade treaties. It has brought an investor state lawsuit against Canada, charging the country with violating its obligations under the North American Free Trade Agreement (NAFTA).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
